tetano
Editor, Senior Moderator
Front Immunol
. 2024 Nov 18:15:1407149.
doi: 10.3389/fimmu.2024.1407149. eCollection 2024. Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development
Xinkang Huan[SUP] #[/SUP][SUP] 1 [/SUP], Jiuyu Zhan[SUP] #[/SUP][SUP] 1 [/SUP], Hongwei Gao[SUP] 1 [/SUP]
Affiliations
The coronavirus disease 2019 (COVID-19) is a respiratory disease with a very high infectious rate caused by the Severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2). Because SARS-CoV-2 is easy to mutate, the continuous emergence of SARS-CoV-2 variant strains not only enhances the infectivity of the SARS-CoV-2 but also brings great obstacles to the treatment of COVID-19. Neutralizing antibodies have achieved good results in the clinical application of the novel coronavirus pneumonia, which can be used for pre-infection protection and treatment of novel coronavirus patients. This review makes a detailed introduction to the mutation characteristics of SARS-CoV-2, focusing on the molecular mechanism of mutation affecting the infectivity of SARS-CoV-2, and the impact of mutation on monoclonal antibody therapy, providing scientific reference for the prevention of SARS-CoV-2 variant strains and the research and development of antibody drugs.
Keywords: COVID-19; SARS-CoV-2; antibody; inevitability; variants.
. 2024 Nov 18:15:1407149.
doi: 10.3389/fimmu.2024.1407149. eCollection 2024. Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development
Xinkang Huan[SUP] #[/SUP][SUP] 1 [/SUP], Jiuyu Zhan[SUP] #[/SUP][SUP] 1 [/SUP], Hongwei Gao[SUP] 1 [/SUP]
Affiliations
- PMID: 39624100
- PMCID: PMC11609190
- DOI: 10.3389/fimmu.2024.1407149
The coronavirus disease 2019 (COVID-19) is a respiratory disease with a very high infectious rate caused by the Severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2). Because SARS-CoV-2 is easy to mutate, the continuous emergence of SARS-CoV-2 variant strains not only enhances the infectivity of the SARS-CoV-2 but also brings great obstacles to the treatment of COVID-19. Neutralizing antibodies have achieved good results in the clinical application of the novel coronavirus pneumonia, which can be used for pre-infection protection and treatment of novel coronavirus patients. This review makes a detailed introduction to the mutation characteristics of SARS-CoV-2, focusing on the molecular mechanism of mutation affecting the infectivity of SARS-CoV-2, and the impact of mutation on monoclonal antibody therapy, providing scientific reference for the prevention of SARS-CoV-2 variant strains and the research and development of antibody drugs.
Keywords: COVID-19; SARS-CoV-2; antibody; inevitability; variants.